XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Intangible Assets, net
 6 Months Ended
Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, net
9. Intangible Assets, net
Intangible assets, net, consist of the following:
June 29,
2024		December 30,
2023
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$177.5 $(15.3)$162.2 $209.2 $(31.5)$177.7 
Acquired technologies131.0 (19.0)112.0 174.7 (45.3)129.4 
Capitalized software development costs50.6 (6.7)43.9 53.9 (15.2)38.7 
Licenses35.9 (5.4)30.5 39.7 (7.4)32.3 
Patents42.1 (16.4)25.7 39.2 (15.2)24.0 
Trademarks19.0 (7.0)12.0 20.1 (7.4)12.7 
Non-compete agreements3.4 (0.4)3.0 6.3 (2.6)3.7 
Licenses-related party7.5 (6.9)0.6 7.5 (6.7)0.8 
Other1.7 (1.1)0.6 1.7 (1.1)0.6 
Total intangible assets subject to amortization, net$468.7 $(78.2)$390.5 $552.3 $(132.4)$419.9 
Intangible assets not subject to amortization:
Trademarks$215.6 $242.4 
Impairment charge— (10.0)
Total trademarks215.6 232.4 
Intangible assets, net$606.1 $652.3 
Finite lived intangible assets have a weighted-average amortization period ranging from twelve years to fourteen years. Total amortization expense for the three months ended June 29, 2024 and July 1, 2023 was $13.1 million and $14.4 million, respectively. Total amortization expense for the six months ended June 29, 2024 and July 1, 2023 was $26.9 million and $28.7 million, respectively.
Total renewal costs for patents and trademarks for the three months ended June 29, 2024 and July 1, 2023 were $0.3 million and $0.2 million, respectively. Total renewal costs for patents and trademarks for the six months ended June 29, 2024 and July 1, 2023 were $0.7 million and $0.5 million, respectively. As of June 29, 2024, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$26.8 
202552.1 
202647.6 
202739.8 
202839.5 
Thereafter184.7 
     Total$390.5 
Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist.
In the third quarter of 2023, declines in the Company’s stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, contributed to a significant decline in the Company’s market capitalization, which led the Company to conclude a trigger event had occurred. As a result, the Company performed a quantitative impairment assessment, which resulted in recording a $7.0 million impairment charge for indefinite-lived trademarks in the non-healthcare reporting unit. In conjunction with this third quarter interim impairment quantitative assessment, the Company concluded that both the healthcare reporting unit’s and non-healthcare reporting unit’s respective estimated fair values exceeded their carrying values. Furthermore, recoverability tests performed for other long-lived assets with finite lives indicated no recoverability issues.
During the fourth quarter of 2023, the Company performed its annual impairment analysis by first electing to complete a qualitative assessment of its indefinite-lived intangible assets. Based on this assessment, the Company determined it was not more likely than not that the fair value of the indefinite lived intangibles within the non-healthcare reporting unit exceeded their carrying values. Accordingly, the Company proceeded to perform a quantitative impairment assessment, which resulted in recording a $3.0 million impairment charge for indefinite-lived trademarks. For purposes of the impairment test, the fair value of indefinite-lived assets were determined using the same methodology as described in Note 18, “Business Combinations.” The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
During the fourth quarter of 2023, the Company also performed its annual goodwill impairment analysis by first electing to complete a qualitative assessment for its healthcare and non-healthcare reporting units. Based on this assessment, the Company concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required for the healthcare reporting unit. However, the Company concluded that it was not more likely than not that the fair value of the non-healthcare reporting unit was greater than its carrying value. Therefore, the Company proceeded to perform a quantitative assessment for its non-healthcare reporting unit.
When a quantitative assessment is required for the impairment test for goodwill, the Company uses a combination of both an income and a market approach to determine the fair value of the reporting unit. The income approach utilized the estimated discounted cash flows for the reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins and a discount rate for the reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and the Company noted that slight changes in these assumptions could have a significant impact on the concluded value.
The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.